Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Mirum Pharmaceuticals ( (MIRM) ).
On December 6, 2025, Mirum Pharmaceuticals announced a merger agreement with Bluejay Therapeutics, aiming to acquire Bluejay’s investigational drug brelovitug, a monoclonal antibody for chronic hepatitis delta virus (HDV). This acquisition, expected to close in the first quarter of 2026, will enhance Mirum’s leadership in rare liver diseases, potentially leading to a biologics license application submission in 2027. Additionally, Mirum has secured a $200 million private placement to support clinical development and commercial activities post-acquisition.
The most recent analyst rating on (MIRM) stock is a Hold with a $69.00 price target. To see the full list of analyst forecasts on Mirum Pharmaceuticals stock, see the MIRM Stock Forecast page.
Spark’s Take on MIRM Stock
According to Spark, TipRanks’ AI Analyst, MIRM is a Neutral.
Mirum Pharmaceuticals shows strong revenue growth and a positive earnings call, indicating potential for future success. However, significant challenges remain, including high leverage, negative profitability, and a recent patent challenge. These factors weigh heavily on the stock’s overall score, highlighting the need for careful management and strategic planning.
To see Spark’s full report on MIRM stock, click here.
More about Mirum Pharmaceuticals
Mirum Pharmaceuticals is a leading rare disease company with a global presence, focusing on developing breakthrough medicines for overlooked conditions. The company’s commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis. Mirum’s clinical-stage pipeline features investigational treatments for primary sclerosing cholangitis, primary biliary cholangitis, and Fragile X syndrome.
Average Trading Volume: 627,094
Technical Sentiment Signal: Buy
Current Market Cap: $3.52B
For a thorough assessment of MIRM stock, go to TipRanks’ Stock Analysis page.